Achmea Investment Management B.V. Lowers Holdings in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA)

Achmea Investment Management B.V. lowered its stake in shares of Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 14.2% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The firm owned 738,385 shares of the company's stock after selling 122,509 shares during the quarter. Achmea Investment Management B.V. owned approximately 0.07% of Teva Pharmaceutical Industries worth $11,349,000 as of its most recent SEC filing.

Several other institutional investors also recently added to or reduced their stakes in TEVA. Oarsman Capital Inc. bought a new position in Teva Pharmaceutical Industries during the fourth quarter valued at about $29,000. Golden State Wealth Management LLC purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $39,000. Marshall & Sterling Wealth Advisors Inc. purchased a new stake in Teva Pharmaceutical Industries in the fourth quarter valued at approximately $44,000. Compagnie Lombard Odier SCmA purchased a new stake in Teva Pharmaceutical Industries in the first quarter valued at approximately $54,000. Finally, Versant Capital Management Inc raised its stake in shares of Teva Pharmaceutical Industries by 437.8% during the first quarter. Versant Capital Management Inc now owns 5,297 shares of the company's stock worth $81,000 after acquiring an additional 4,312 shares in the last quarter. Institutional investors own 54.05% of the company's stock.

Insider Activity

In other news, EVP Matthew Shields sold 6,206 shares of the business's stock in a transaction on Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president now owns 9,989 shares in the company, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. Company insiders own 0.49% of the company's stock.

Analyst Ratings Changes

Several research firms have commented on TEVA. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research note on Wednesday, May 28th. They set a "buy" rating and a $25.00 price target on the stock. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a report on Thursday, May 22nd. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and raised their target price for the stock from $21.00 to $23.00 in a report on Monday, May 12th. UBS Group cut their target price on shares of Teva Pharmaceutical Industries from $24.00 to $23.00 and set a "buy" rating on the stock in a report on Thursday. Finally, The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. Eight equities research analysts have rated the stock with a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company currently has a consensus rating of "Buy" and a consensus target price of $24.13.

Teva Pharmaceutical Industries Trading Up 1.2%

NYSE:TEVA traded up $0.20 during trading hours on Friday, hitting $16.76. The company had a trading volume of 8,942,158 shares, compared to its average volume of 10,279,391. The company has a market capitalization of $19.22 billion, a PE ratio of -14.57, a price-to-earnings-growth ratio of 0.85 and a beta of 0.60. The stock has a 50-day moving average price of $16.66 and a 200 day moving average price of $17.40. Teva Pharmaceutical Industries Ltd. has a 52 week low of $12.47 and a 52 week high of $22.80. The company has a debt-to-equity ratio of 2.59, a current ratio of 1.03 and a quick ratio of 0.74.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last released its quarterly earnings results on Wednesday, May 7th. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.47 by $0.05. Teva Pharmaceutical Industries had a negative net margin of 7.74% and a positive return on equity of 45.44%. The business had revenue of $3.89 billion for the quarter, compared to analysts' expectations of $3.99 billion. During the same quarter in the previous year, the business posted $0.48 earnings per share. The firm's revenue for the quarter was up 1.9% compared to the same quarter last year. On average, equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 EPS for the current fiscal year.

Teva Pharmaceutical Industries Profile

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.